Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference
Cullinan Oncology (Nasdaq: CGEM) has announced that CFO Jeff Trigilio will present at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 11:45 am EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cullinan Oncology (Nasdaq: CGEM) has announced that CFO Jeff Trigilio will present at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 11:45 am EDT. The presentation will be accessible only to registered attendees through the Needham conference portal. Interested investors can schedule meetings with Trigilio by contacting their Needham representative. Cullinan Oncology is focused on developing a diversified pipeline of targeted and immuno-oncology therapeutic candidates to drive shareholder returns.
Details
News Market Reaction – CGEM
The recorded move for CGEM in the trading session of this news was +2.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company’s Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20th Annual Needham Virtual Healthcare Conference.
Event: Needham Virtual Healthcare Conference
Date: Tuesday, April 13th
Time: 11:45am EDT
Location: Virtual
The presentation will be accessible through the Needham conference portal for registered attendees only. Investors interested in scheduling a meeting with Mr. Trigilio should contact their Needham & Company representative.
About Cullinan Oncology
Cullinan Oncology is a biopharmaceutical company that seeks to drive shareholder returns by focusing on the patient. The Company’s strategy is to build a diversified pipeline of targeted and immuno-oncology therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. Learn more about Cullinan at www.cullinanoncology.com.
Contacts:
Investor Relations
investors@cullinanoncology.com
Jeff Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.